Facebook
X
LinkedIn
Forward
Genetics in Clinical Cancer Care: From Family Reunions to the Frontline of Developmental Therapeutics
April 17, 2020 to April 19, 2020
DUE TO COVID-19, OUR CONFERENCE IS MOVING ONLINE! JOIN US FROM ANYWHERE IN THE WORLD!
Join us for the 9th Annual International Clinical Cancer Genetics and Genomics Conference in conjunction with the Personalized Cancer Care Consortium!
This activity will provide an interdisciplinary educational forum in which to update state-of-the-art science including novel therapies for inherited cancers, discuss real-world cases, curate interesting pedigrees, and prepare case summaries to disseminate new knowledge in translational genomics and evidence-based clinical management of high-risk patients and their family members.
This activity will provide an interdisciplinary educational forum in which to update state-of-the-art science including novel therapies for inherited cancers, discuss real-world cases, curate interesting pedigrees, and prepare case summaries to disseminate new knowledge in translational genomics and evidence-based clinical management of high-risk patients and their family members.
Click on the "Get Started!" tab to find out more!
 This activity is brought to you in partnership with City of Hope. |
Target Audience
This activity is designed for physicians, physician assistants, advanced nurse practitioners, genetic counselors, oncology nurses, and other healthcare professionals currently providing oncology care and cancer genetics risk assessment services or initiating such care and services in their healthcare system. Special efforts will be made to educate clinicians practicing in geographically or socioeconomically underserved communities.
Learning Objectives
At the conclusion of this activity, participants will be able to:
- Recall advanced concepts in genetics, genomics, and next generation sequencing (NGS) technologies;
- Analyze controversies in cancer risk assessment and genetic testing including the integration of polygenic risk scores;
- Recognize how scientific advances in Lynch syndrome and other inherited solid tumors and hematologic malignancies can improve the clinical management of patients;
- Discuss how the integration of novel cancer therapies based on genomic alterations in tumor tissue may reveal germline mutations that can guide patient management;
- Recognize the limitations of genomic testing as it relates to both cancer risk as well as therapeutic selection, including variants of uncertain significance and in silico predictions;
- Identify how a globally-informed perspective on experimental therapeutics for rare cancers including immunotherapy can improve patient outcomes;
- Discuss how emerging concepts in cancer interception and cancer risk modifiers including lifestyle and chemoprevention can impact disease management strategies;
- State the ethical, legal, and social implications of genomic testing in diverse populations.
American Board of Internal Medicine MOC Part II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please Note: The credit claiming process will close three months after the conference end date. Requests to claim credit after three months will be subject to additional fees.
Claiming Credit: Click the button below.
Warning! If you are claiming MOC II credit for ABIM, please be sure that you have provided your specialty board information in your profile.
For additional assistance on how to add this to your profile, please see:
How To - Adding Specialty Board Information.pdf
For additional assistance on how to add this to your profile, please see:
How To - Adding Specialty Board Information.pdfPlease login or create an account to proceed.